- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.10. | Biotech reverse mergers rebound to highest level since 2021 as PIPEs flood market: report | ||
| 21.10. | Advocacy organization launches data dashboard to better assess how clinical trial sites perform | ||
| 20.10. | Industry at a 'turning point' with growth dominated by commercial leaders: EY report | ||
| 20.10. | Lycia aims for $228M IPO to generate data on food allergy rival to Xolair | ||
| 20.10. | Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition | ||
| 20.10. | Hengrui has become the go-to source of China biopharma innovation. What's its secret? | ||
| 20.10. | Israeli biotech's inhaled exosome therapy reduces respiratory failure in phase 2 study | ||
| 20.10. | Pfizer makes 'business decision' to end phase 2 trial of autoimmune drug as program's future uncertain | ||
| 20.10. | AstraZeneca taps Oracle to help improve recruitment for clinical trials | ||
| 20.10. | Ambrose Healthcare inks $181M deal for former Pfizer target AM-Pharma | ||
| 19.10. | Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery | ||
| 19.10. | Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC | ||
| 19.10. | Gilead 'sitting on a foundational asset' after oral UC drug's phase 2 win | ||
| 19.10. | Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win | ||
| 19.10. | Enlivex lays off 60% of employees, scraps preclinical R&D and gives execs 'substantial' salary cuts | ||
| 19.10. | Disc spins past FDA rejection with 'overwhelmingly positive' phase 3 data | ||
| 19.10. | Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh | ||
| 19.10. | Roche returns to China's ADC powerhouse Hansoh for $15B biobucks pact | ||
| 19.10. | Immune Boost Capital Invests in Orthrus Therapeutics to Advance Antigen-Specific Immune Tolerance for Autoimmune Disease | ||
| 19.10. | Siemens Healthineers partners with Paradromics to build out new imaging system to support BCIs | ||
| 19.10. | Beyond Amyloid: New Insights into Tau Pathology and Disease Progression with eMTBR | ||
| 19.10. | AbbVie's next-gen Crohn's disease combo beats Skyrizi in phase 2 trial | ||
| 19.10. | Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate | ||
| 16.10. | Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions | ||
| 16.10. | From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.